BioNTech SE(BNTX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year, despite a decrease in COVID-19 vaccine revenues [27] - R&D expenses were approximately EUR 2.1 billion, a slight decrease from the prior year, enabled by cost savings and positive effects from cost-sharing with BMS [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - An adjusted non-IFRS net loss of EUR 117 million was reported for 2025 [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [6] - Significant progress was made in oncology programs, with over 4,000 patients enrolled across phase II and phase III studies [6] - The company executed strategic deals, including acquiring Biotheus and CureVac, to strengthen its oncology pipeline [7] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 compared to 2025, driven by declines in both European and U.S. markets [30] - The U.S. market is expected to be competitive and dynamic, impacting revenue generation [30] - In Germany, direct sales of COVID-19 vaccines will significantly affect the company's top line [31] Company Strategy and Development Direction - The company aims to become a multi-product company by 2030, focusing on oncology and personalized medicine [10] - Key priorities for 2026 include accelerating late-stage development of oncology assets, building momentum in combination-based approaches, and evolving to a tumor-centric clinical development program [8] - The company plans to leverage its diverse clinical assets for combination strategies to address multiple lines of treatment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [8] - The transition to a new independent company for next-generation mRNA innovations is expected to enhance BioNTech's strategic focus [10] - Management anticipates a sustained cadence of event-driven late-stage readouts from 2026 to 2030, with significant potential to improve patient outcomes [9] Other Important Information - The company will supplement its IFRS reporting with adjusted non-IFRS measures to provide better context for business performance [28] - A binding agreement for the new company is expected to be signed by the end of the first half of 2026 [11] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [38][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [46] Question: Why is the management transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech's contribution will relate to certain rights and mRNA technologies, not cash [54] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95]